Chemokines: Immunology's high impact factors

Nature Immunology

Volumn 2, Issue 2, 2001, Pages 95-101

  Mackay, Charles R ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; VIRUS RECEPTOR;

ANIMAL; B LYMPHOCYTE; BIOLOGICAL MODEL; CELL COMMUNICATION; CELL DIFFERENTIATION; CYTOLOGY; DRUG ANTAGONISM; GENETIC POLYMORPHISM; GENETICS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFLAMMATION; LEUKOCYTE; MUCOSAL IMMUNITY; REVIEW; T LYMPHOCYTE; VASCULAR ENDOTHELIUM;

ANIMALS; B-LYMPHOCYTES; CELL COMMUNICATION; CELL DIFFERENTIATION; CHEMOKINES; CYTOKINES; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNE TOLERANCE; IMMUNITY, MUCOSAL; INFLAMMATION; LEUKOCYTES; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; RECEPTORS, CHEMOKINE; RECEPTORS, VIRUS; T-LYMPHOCYTES;

EID: 0035256994     PISSN: 15292908     EISSN: None     Source Type: Journal    
DOI: 10.1038/84298     Document Type: Review

References (99)

1. Devreotes, P. N. & Zigmond, S. H. Chemotaxis in eukaryotic cells: a focus on leukocytes and dictyostelium. Ann. Rev. Biol. 4, 649-586 (1988).
2. Zlotnik, A. & Yoshie, O. Chemokines: a new classification system and their rote in immunity. Immunity 12, 121-127 (2000).
3. Yoshimura, T. et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc. Natl Acad. Sci. USA 84, 9233-9237 (1987).
4. Rossi, D. & Zlotnik, A. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18, 217-242 (2000).
5. Holmes, W. E., Lee, J., Kuang, W. J., Rice, G. C. & Wood, W. I. Structure and functional expression of a human interleukin-8 receptor. Science 253, 1278-1280 (1991).
6. Gerard, C. & Rollins, B. Chemokines in disease. Nature Immunol 2, 108-115 (2001).
7. Zou, Y. R., Kottmann, A. H., Kuroda, M.,Taniuchi, I. & Littman, D. R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393, 595-599 (1998).
8. Nagasawa, T. et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1, Nature 382, 635-638 (1996).
9. Butcher, E. C. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67, 1033-1036 (1991).
10. Springer, T. A.Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76, 301-314 (1994).
11. Bargatze, R. F. & Butcher. E. C. Rapid G protein-regulated activation event involved in lymphocyte binding to high endothelial venules. J. Exp. Med. 178, 367-372 (1993).
12. Tanaka, Y. et al. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β. Nature 361, 79-82 (1993).
13. Kitayama, J., Mackay. C. R., Ponath, P. D. & Springer,T. A,The C-C chemokine receptor CCR3 participates in stimulation of eosinophil arrest on inflammatory endothelium in shear flow. J. Gin. Invest 101, 2017-2024 (1998).
14. Gerszten, R. E. et al. MCP-I and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398, 718-723 (1999).
15. Campbell, J. J. et al. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 279, 381-384 (1998).
16. Ponath, P. D. et al. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J. Clin. Invest 97, 604-612 (1996).
17. Bleul, C. C., Schultze, J. L & Springer, T. A. B lymphocyte chemotaxis regulated in association with microanatomic localization, differentiation state, and B cell receptor engagement. J. Exp. Med. 187, 753-762 (1998).
18. Bowman, E. P. et al. Developmental switches in chemokine response profiles during B cell differentiation and maturation. J. Exp. Med. 191, 1303-1318 (2000).
19. Guinamard, R., Okigaki, M., Schlessinger, J. & Ravetch, J. V. Absence of marginal zone B cells in Pyk2-deficient mice defines their role in the humoral response. Nature Immunol. 1, 31-36 (2000).
20. Bleul, C. C. & Boehm, T. Chemokines define distinct microenvironments in the developing thymus. Eur. J Immunol 30, 3371-3379 (2000).
21. Campbell, J. J., Pan, J. & Butcher, E C. Cutting edge: developmental switches in chemokine responses during T cell maturation. J. Immunol 163, 2353-2357 (1999).
22. Sallusto, F., Mackay, C. R. & Lanzavecchia, A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18, 593-620 (2000).
23. Campbell, J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 400, 776-780 (1999).
24. Bleul, C. C., Wu, L, Hoxie, J. A., Springer, T. A. & Mackay, C. R. The HIV coreceptors CXCR4 and CCRS are differentially expressed and regulated on human T lymphocytes. Proc. Natl Acad. Sci. USA 94, 1925-1930 (1997).
25. Zabel, B. A. et al. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectivefy expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J. Exp. Med. 190, 1241-1256 (1999).
26. Sallusto, H. Mackay, C. R. & Lanzavecchia, A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells. Science 277, 2005-2007 (1997).
27. Sallusto, E, Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712 (1999).
28. Dieu, M. C. et al. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188, 373-386 (1998).
29. Cook, D. N. et al. CCR6 mediates dendritic cell localization, lymphocyte homeostasis and immune responses in mucosal tissue, Immunity 12, 495-503 (2000).
30. Sallusto, F. et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 28, 2760-2769 (1998).
31. Sozzani, S. et al. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J. Immunol. 161, 1083-1086 (1998).
32. Adema, G. J. et al. A dendritic-cell-derived C-C chernokine that preferentially attracts naive T cells. Nature 387, 713-717 (1997).
33. Saltusto, F. & Lanzavecchia, A. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J. Exp. Med. 189, 611-614 (1999).
34. Heath, W. R., Kurts, C., Miller, J. F. A. P. & R., C. F. Cross-tolerance:A pathway for inducing tolerance to peripheral tissue antigens. J. Exp. Med. 187, 1549-1553 (1998).
35. Moser, B. & Loetscher, P. Lymphocyte traffic control by chemokines. Nature Immunol. 2, 123-128 (2001).
36. Cyster, J. G. Chemokines and cell migration in secondary lymphoid organs. Science 286, 2098-2102 (1999).
37. Mackay, C. R. Follicular homing T helper cells and the ThI/Th2 paradigm. J. Exp. Med. 192, 31-34 (2000).
38. Gunn, M. D. et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189, 451-460 (1999).
39. Forster, R. et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the, spleen. Cell 87, 1037-1047 (1996).
40. Forster, R. et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99, 23-33 (1999).
41. Ansel, K. M. et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406, 309-314 (2000).
42. Yoshie, O., Imai. T. & Nomiyama, H. Novel lymphocyte-specific CC chemokines and their receptors. J. leukoc. Biol. 62, 634-644 (1997).
43. Sallusto, F., Lanzavecchia, A, & Mackay. C. R. Chemokines and chemokine receptors in T-cell priming and Th1/Th2- mediated responses.Immunol.Today 19, 568-574 (1998).
44. Warnock, R. A. et al. The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothefial venules. J. Exp. Med. 191, 77-88 (2000).
45. Gunn, M. D. et al. A chemokine expressed in lymphoid high endoihelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc. Natl Acad. Sci. USA 95, 258-263 (1998).
46. Stein, J. V. et al. The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. J. Exp. Med. 191, 61-76 (2000).
47. Gunn, M. D. et al.A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 391, 799-803 (1998).
48. Ngo, V. N. et al. Lymphotoxin α/β and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med 189, 403-412 (1999).
49. Ansel, K. M., McHeyzer-Williams, L. J., Ngo, V. N., McHeyzer-Wiliams, M. G. & Cyster, J. G. In vivo-activated CD4T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines. J. Exp. Med. 190, 1123-1134 (1999).
50. Schaerli, P. et al. CXCR5 expression defines follicular homing T cells with B cell helper function. J. Exp. Med. 192, 1553-1562 (2000).
51. Breitfeld, D. et al. Follicular B helper T cells express CXCR5, localize to B cell follicles and support immunoglobulin production. J. Exp. Med. 192, 1545-1552 (2000).
52. Li, L et al. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J. Immunol. 162, 2477-2487 (1999).
53. Shinkai, A. et al. A novel human CC chemokine, eotaxin-3, which is expressed in 1L-4- stimulated vascular endothelial cells, exhibits potent activity toward eosinophils. J. Immunol. 163, 1602-1610 (1999).
54. Ying, S. et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur. J. Immunol. 27, 3507-3516 (1997).
55. Sallusto, F., Lenig. D., Mackay. C. R. & Lanzavecchia, A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187, 875-883 (1998).
56. Heath, H. et al. Chemokine receptor usage by human eosinophils.The importance of CCR3 demonstrated using an antagonistic monoclonal antibody. J. Clin. Invest 99, 178-184 (1997).
57. Uguccioni, M. et al. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines. J. Clin, Invest. 100, 1137-1143 (1997).
58. Ochi, H. et al. T helper cell type 2 cytokine-mediated comitogenic responses and CCR3 expression during differentiation of human mast cells in vitro. J. Exp. Med 190, 267-280 (1999).
59. Zingont, A. et al. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J. Immunol. 161, 547-551 (1998).
60. Lloyd, C. M. et al. CC chemokine receptor (CCR) 3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J. Exp. Med 191, 265-274 (2000).
61. Bonecchi, R. et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J. Exp. Med. 187, 129-134 (1998).
62. Randolph, D. A., Huang, G., Carruthers, C. J., Bromley, L E. & Chaplin, D. D.The role of CCR7 in TH1 and TH2 cell localization and delivery of B cell help in vivo. Science 286, 2159-2162 (1999).
63. Loetscher, P. et al. CCR5 is characteristic of Th1 lymphocytes. Nature 39, 344-345 (1998).
64. Balashov, K. E., Rottman, J. B., Weiner, H. L. & Hancock, W. W. CCRS(+)and CXCR3(+)T cells are increased in multiple sclerosis and their ligands MIP-1α and 1P-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA 96, 6873-6878 (1999).
65. Sauty, A. et al. The T cell-specific CXC chemokines 1P-10, Mig, and 1-TAC are expressed by activated human bronchial epithelial cells. J. Immunol. 162, 3549-3558 (1999).
66. Qin, S. et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest 101, 746-754 (1998).
67. Luther, S. A., Lopez, T., Bai, W., Hanahan, D. & Cyster, J. G. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 12, 471-481 (2000).
68. H2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404, 407-411 (2000).
69. Lukacs, N. W. et al. C-C chemokines differentially alter interteukin-4 production from lymphocytes. Am. J. Pothol. 150, 1861-1868 (1997).
70. Kunkel, E. J. et al. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissuespecific chemokines as an organizing principle in regional immunity. J. Exp. Med. 192, 761-768 (2000).
71. Morales, J. et al. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc. Natl Acad. Sci. USA 96, 14470-14475 (1999).
72. Homey, B. et al. Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2. CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/1LC). J. Immunol. 164, 3465-3470 (2000).
73. Huang, Y. et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med. 2, 1240-1243 (1996).
74. Berger, E. A., Murphy, P. M. & Farber, J. M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol 17, 657-700 (1999).
75. Moore, J. P. Coreceptors: implications for HIV pathogenesis and therapy. Science 276, 51-52 (1997).
76. Murphy, P. M.Viral exploitation and subversion of the immune system through chemokine mimicry. Nature Immunol. 2, 159-166 (2001).
77. Lalani, A. S. et al. Use of chemokine receptors by poxviruses. Science 286, 1968-1971 (1999).
78. Lin, C. L et al. Macrophage-tropic HIV Induces and Exploits Dendritic Cell Chemotaxis. J. Exp. Med. 192, 587-594 (2000).
79. Sozzani, S. et al.The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood 92, 4036-4039 (1998).
80. Kledal, T. N. et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpes virus. Science 277, 1656-1659 (1997).
81. Boshoff, C. et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. Science 278, 290-294 (1997).
82. McDermott, D. H. et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS), Lancet 352, 866-870 (1998).
83. Blanpain, C. et al. Multiple nonfunctional alleles of CCRS are frequent in various human populations. Blood 6, 1638-1645 (2000).
84. Wu, L et al. CCRS levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J. Exp. Med. 185, 1681-1691 (1997).
85. Gomez-Reino, J. J. et al. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum. 42, 989-992 (1999).
86. Sellebjerg. F., Madsen, H. O., Jensen, C. V., Jensen, J. & Garred, P. CCR5 Δ32, matrix metalloproteinase9 and disease activity in multiple sclerosis. J. Neuroimmunol. 102, 98-106 (2000).
87. Teuscher, C. et al. Sequence polymorphisms in the chemokines Scya1 (TCA-3), Scya2 (monocyte chemoattractant protein (MCP)-1), and Scya12 (MCP-5) are candidates for eae7,a locus controlling susceptibility to monophasic remitting/nonrelapsing experimental allergic encephalomyelitis. J. Immunol. 163, 2262-2266 (1999).
88. Cameron, M. J. et al. Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type 1 diabetes. J. Immunol. 165, 1102-1110 (2000).
89. Strieter, R. M. et al. "The good, the bad. and the ugly." The role of chemokines in models of human disease. J. Immunol. 156, 3583-3586 (1996).
90. Baba, M. et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective antiHIV-1 activity. Proc. Natl. Acad. Sci. USA 96, 5698-5703 (1999).
91. Baggiolini, M. & Moser, B, Blocking chemokine receptors. J. Exp. Med. 186, 1189-1191 (1997).
92. Murphy, P. M. et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52, 145-176 (2000).
93. Gonzalo, J. A. et al. The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness. J. Exp. Med. 188, 157-167 (1998).
94. Dabbagh, K. et al. Local blockade of allergic airway hyperreactivity and inflammation by the poxvirusderived pan-CC-chemokine inhibitor vCCI. J. Immunol. 165, 3418-3422 (2000).
95. Gu, L et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 2, 275-281 (1998).
96. + mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394, 894-897 (1998).
97. Gosling, J. et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103, 773-778 (1999).
98. Tesch, G. H., Maifert, S., Schwarting, A., Rollins, B. J. & Kelley, Y. R. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J. Exp. Med. 190, 1813-1824 (1999).
99. Gao, W. et al. Targeting of the chemokine receptor CCRI suppresses development of acute and chronic cardiac allograft rejection. J. Clin. Invest 105, 35-44 (2000).